Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer

被引:2
作者
Han, Xu [1 ]
Li, Hui [1 ]
Dong, Sha-Sha [1 ]
Zhou, Shui-Ying [1 ]
Wang, Cai-Hong [2 ]
Guo, Lin [1 ]
Yang, Jie [1 ]
Zhang, Gang-Ling [1 ]
机构
[1] Baotou Canc Hosp, Dept Breast Surg, 18 Tuanjie St, Baotou 014030, Inner Mongolia, Peoples R China
[2] Baotou Canc Hosp, Dept Operating Room, Baotou 014030, Inner Mongolia, Peoples R China
关键词
Breast cancer; Neoadjuvant therapy; Triple evaluation method; Physical examination; Color Doppler ultrasound; Magnetic resonance imaging; PATHOLOGICAL RESPONSE; INCOHERENT MOTION; CHEMOTHERAPY;
D O I
10.1186/s12957-023-02998-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveTo analyze the factors related to the efficacy of neoadjuvant therapy for breast cancer and find appropriate evaluation methods for evaluating the efficacy of neoadjuvant therapyMethodsA total of 143 patients with breast cancer treated by neoadjuvant chemotherapy at Baotou Cancer Hospital were retrospectively analyzed. The chemotherapy regimen was mainly paclitaxel combined with carboplatin for 1 week, docetaxel combined with carboplatin for 3 weeks, and was replaced with epirubicin combined with cyclophosphamide after evaluation of disease progression. All HER2-positive patients were treated with simultaneous targeted therapy, including trastuzumab single-target therapy and trastuzumab combined with pertuzumab double-target therapy. Combined with physical examination, color Doppler ultrasound, and magnetic resonance imaging (MRI), a systematic evaluation system was initially established-the "triple evaluation method." A baseline evaluation was conducted before treatment. The efficacy was evaluated by physical examination and color Doppler every cycle, and the efficacy was evaluated by physical examination, color Doppler, and MRI every two cycles.ResultsThe increase in ultrasonic blood flow after treatment could affect the efficacy of monitoring. The presence of two preoperative time-signal intensity curves is a therapeutically effective protective factor for inflow. The triple evaluation determined by physical examination, color Doppler ultrasound, and MRI in determining clinical efficacy is consistent with the effectiveness of the pathological gold standard.ConclusionThe therapeutic effect of neoadjuvant therapy can be better evaluated by combining clinical physical examination, color ultrasound, and nuclear magnetic resonance evaluation. The three methods complement each other to avoid the insufficient evaluation of a single method, which is convenient for most prefecty-level hospitals. Additionally, this method is simple, feasible, and suitable for promotion.
引用
收藏
页数:9
相关论文
共 32 条
[1]   Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients [J].
Baumgartner, Annina ;
Tausch, Christoph ;
Hosch, Stefanie ;
Papassotiropoulos, Barbel ;
Varga, Zsuzsanna ;
Rageth, Christoph ;
Baege, Astrid .
BREAST, 2018, 39 :19-23
[2]  
[陈曼 Chen Man], 2013, [中国超声医学杂志, Chinese Journal of Ultrasonic in Medicine], V29, P691
[3]   Accuracy of physical examination, ultrasonography, and magnetic resonance imaging in predicting response to neo-adjuvant chemotherapy for breast cancer [J].
Chen Man ;
Zhan Wei-wei ;
Han Bao-san ;
Fei Xiao-chun ;
Jin Xiao-long ;
Chai Wei-min ;
Wang Deng-bing ;
Shen Kun-wei ;
Wang Wen-ping .
CHINESE MEDICAL JOURNAL, 2012, 125 (11) :1862-1866
[4]   Optimization of intra-voxel incoherent motion measurement in diffusion-weighted imaging of breast cancer [J].
Chen, Wenjing ;
Zhang, Juan ;
Long, Dan ;
Wang, Zhenchang ;
Zhu, Jian-Ming .
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2017, 18 (03) :191-199
[5]  
China Breast Cancer neoadjuvant Therapy Expert Group, 2022, CHINA ONCOL, V32, P80, DOI [10.19401/j.cnki.1007-3639.2022.01.011, DOI 10.19401/J.CNKI.1007-3639.2022.01.011]
[6]   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172
[7]   Can the Neutrophil to Lymphocyte Ratio Predict Complete Pathologic Response to Neoadjuvant Breast Cancer Treatment? A Systematic Review and Meta-analysis [J].
Cullinane, Carolyn ;
Creavin, Ben ;
O'Leary, Donal Peter ;
O'Sullivan, Martin J. ;
Kelly, Louise ;
Redmond, Henry Paul ;
Corrigan, Mark Antony .
CLINICAL BREAST CANCER, 2020, 20 (06) :E675-E681
[8]   The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study [J].
Di Cosimo, Serena ;
Triulzi, Tiziana ;
Pizzamiglio, Sara ;
De Cecco, Loris ;
de Azambuja, Evandro ;
Fumagalli, Debora ;
Putzai, Lajos ;
Harbeck, Nadia ;
Izquierdo, Miguel ;
de la Pena, Lorena ;
Daidone, Maria Grazia ;
Huober, Jens ;
Gori, Stefania ;
Cinieri, Saverio ;
Torri, Valter ;
Baselga, Jose ;
Piccart, Martine ;
de Braud, Filippo G. ;
Apolone, Giovanni ;
Verderio, Paolo ;
Tagliabue, Elda .
EUROPEAN JOURNAL OF CANCER, 2019, 118 :1-9
[9]  
Expert Panel on Breast Imaging:, 2017, J Am Coll Radiol, V14, pS462, DOI 10.1016/j.jacr.2017.08.037
[10]   An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer [J].
Fu, Changfang ;
Liu, Yu ;
Han, Xinghua ;
Pan, Yueyin ;
Wang, Hong-qiang ;
Wang, Hongzhi ;
Dai, Haiming ;
Yang, Wulin .
FRONTIERS IN IMMUNOLOGY, 2021, 12